The Community Pharmacist's Role in Reducing Cardiovascular Risk Factors in Lebanon: A Longitudinal Study.
| Autor: | Fahs IM; School of Pharmacy, Lebanese International University, Mouseitbah, Lebanon., Hallit S; Faculty of Pharmacy, Saint-Joseph University of Beirut, Beirut, Lebanonsouheilhallit@Hotmail.com.; Lebanese University, Faculty of Pharmacy, Beirut, Lebanonsouheilhallit@Hotmail.com.; Holy Spirit University of Kaslik, Faculty of Medicine and Medical Sciences, Kaslik, Lebanonsouheilhallit@Hotmail.com.; Research Department, Psychiatric Hospital of the Cross, Jal Eddib, Lebanonsouheilhallit@Hotmail.com.; Occupational Health Environment Research Team, U1219 BPH Bordeaux Population Health Research Center Inserm, Université de Bordeaux, Bordeaux, Francesouheilhallit@Hotmail.com.; INSPECT-LB: Institut National de Sante Publique, Epidemiologie Clinique et Toxicologie, Faculty of Public Health, Lebanese University, Beirut, Lebanonsouheilhallit@Hotmail.com., Rahal MK; School of Pharmacy, Lebanese International University, Mouseitbah, Lebanon., Malaeb DN; School of Pharmacy, Lebanese International University, Mouseitbah, Lebanon. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Medical principles and practice : international journal of the Kuwait University, Health Science Centre [Med Princ Pract] 2018; Vol. 27 (6), pp. 508-514. Date of Electronic Publication: 2018 Jun 13. |
| DOI: | 10.1159/000490853 |
| Abstrakt: | Objective: To assess the role of the pharmacist in modifying risk factors for cardiovascular disease (CVD) among Lebanese adults in urban and rural areas. Methods: In a prospective survey, 865 out of 1,000 participants aged ≥45 years, previously interviewed, agreed to be followed at 1 and 2 years time points. Parameters including blood pressure, lipid profile, blood glucose, average number of risk factors, and atherosclerotic CVD (ASCVD) risk were assessed and evaluated at the beginning of the study, then after 1 and 2 years. Results: During both follow-ups, the mean average body mass index and systolic blood pressure decreased significantly and the lipid profile improved significantly. Further significant improvements in ASCVD risk occurred during the second follow-up. Monitoring parameters revealed significant improvements as well. Conclusion: This study showed that a plan that includes pharmacists, who regularly monitor and follow-up patients, could improve CVD prevention through the reduction of risk factors. (©2018The Author(s) Published by S. Karger AG, Basel.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|